Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 4-armed trial	850 children aged 12–17 years, 699 (82%) treated for at least one migraine attack In review	Proportion of children with adverse effects 79/178 (44%) with zolmitriptan 10 mg 45/174 (26%) with zolmitriptan 5 mg 49/171 (29%) with zolmitriptan 2.5 mg 22/176 (13%) with placebo	Significance not assessed
RCT 3-armed trial	32 children, 29 (90%) of whom were included in the intention-to-treat analysis	Proportion of children with adverse effects 34% with zolmitriptan 13% with placebo Absolute numbers not reported	P <0.05	Effect size not calculated	placebo